MYOMA
MCID: MYM001
MIFTS: 54

Myoma (MYOMA)

Categories: Cancer diseases, Muscle diseases, Reproductive diseases

Aliases & Classifications for Myoma

MalaCards integrated aliases for Myoma:

Name: Myoma 12 54 43 15 71
Neoplasms, Muscle Tissue 43 71
Muscle Benign Neoplasm 12 15
Myomatous Neoplasm 12 71
Benign Neoplasm of the Muscle 12
Muscle Tissue Neoplasm 12
Neoplasm of Muscle 12
Muscle Neoplasms 54
Muscle Neoplasm 12
Myomatous Tumor 12
Myomas 15

Classifications:



External Ids:

Disease Ontology 12 DOID:2691 DOID:461
NCIt 49 C4063 C4882
SNOMED-CT 67 115228006 66357004
ICD10 32 D21
UMLS 71 C0027086 C0027664 C0282606

Summaries for Myoma

Disease Ontology : 12 A muscle benign neoplasm that is characterized as benign hyperplastic lesions of uterine smooth muscle cells.

MalaCards based summary : Myoma, also known as neoplasms, muscle tissue, is related to uterus leiomyosarcoma and amenorrhea, and has symptoms including muscle weakness, myoclonus and myalgia. An important gene associated with Myoma is PGR (Progesterone Receptor), and among its related pathways/superpathways are Development Angiotensin activation of ERK and Gastric cancer. The drugs Leuprolide and Dimenhydrinate have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and cervix, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia : 74 Myomas are benign, monoclonal tumors of the smooth muscle cells of the myometrium. They are composed of... more...

Related Diseases for Myoma

Diseases related to Myoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 445)
# Related Disease Score Top Affiliating Genes
1 uterus leiomyosarcoma 32.1 PGR CALD1 CALCA
2 amenorrhea 31.3 LEP GNRH1 CYP19A1
3 leiomyoma 31.3 PGR MED12 HMGA2 GNRH1 FH ESR1
4 ovarian cyst 31.2 MUC16 GNRH1 CYP19A1
5 endometriosis 31.2 TP53 PGR MUC16 GNRH1 ESR1 CYP19A1
6 adenomyosis 31.1 TP53 PGR OXT GNRH1 ESR1 CYP19A1
7 benign metastasizing leiomyoma 31.0 PGR CYP19A1
8 leiomyosarcoma 30.9 TP53 PGR MED12 HMGA2 FH ESR1
9 leiomyomatosis 30.9 PGR MED12 GNRH1 FH ESR1
10 endometrial hyperplasia 30.8 TP53 PGR KRAS ESR1 CYP19A1
11 endometrial stromal sarcoma 30.8 TP53 PGR ESR1 CYP19A1 CALD1
12 intravenous leiomyomatosis 30.8 PGR MED12 HMGA2 ESR1 CALD1
13 endometritis 30.8 PGR OXT ESR1
14 pleomorphic lipoma 30.7 PGR HMGA2
15 cystic teratoma 30.7 TP53 MUC16 KRAS
16 cystadenoma 30.6 PGR MUC16 FH
17 adenomyoma 30.6 PGR MED12 GNRH1 ESR1 CALD1
18 mesenchymal cell neoplasm 30.6 TP53 HMGA2 CALD1
19 ureteral obstruction 30.5 TP53 GNRH1 EPO
20 pelvic organ prolapse 30.5 TP53 PGR MFN2 ESR1
21 endometrial cancer 30.4 TP53 PGR MUC16 KRAS GNRH1 ESR1
22 vaginal discharge 30.4 PGR OXT GNRH1 ESR1 CYP19A1
23 cutaneous leiomyosarcoma 30.4 FH CALD1
24 cellular leiomyoma 30.4 MED12 CALD1
25 endometrial adenocarcinoma 30.4 TP53 PGR KRAS ESR1 EGFR
26 liver leiomyoma 30.4 PGR ESR1
27 estrogen excess 30.3 PGR GNRH1 ESR1 CYP19A1
28 endometriosis of ovary 30.3 PGR GNRH1 ESR1 CYP19A1
29 carcinosarcoma 30.3 TP53 PGR KRAS EGFR
30 neurofibroma 30.3 TP53 KITLG EGFR
31 vaginal cancer 30.2 TP53 PGR ESR1 CALD1
32 leiomyoma cutis 30.2 MED12 FH
33 in situ carcinoma 30.2 TP53 PGR ESR1 EGFR CYP19A1
34 meningioma, familial 30.2 TP53 PGR ESR1 EGFR
35 atypical polypoid adenomyoma 30.2 MED12 CALD1
36 leiomyoma, uterine 30.1 PGR OXT MUC16 MED12 HPSE2 HMGA2
37 smooth muscle tumor 30.1 PGR MED12 HMGA2 FH ESR1 CALD1
38 adhesions of uterus 30.0 PGR MFN2
39 breast fibroadenoma 30.0 TP53 PGR MED12 HMGA2 ESR1 CYP19A1
40 ovarian serous cystadenocarcinoma 30.0 TP53 PGR MUC16 KRAS ESR1 EGFR
41 vulvar leiomyoma 29.9 PGR HMGA2 ESR1 CALD1
42 ovarian disease 29.9 TP53 PGR MUC16 LEP GNRH1 ESR1
43 bizarre leiomyoma 29.6 TP53 PGR MED12 FH ESR1 CALD1
44 body mass index quantitative trait locus 11 29.5 TP53 OXT MFN2 LEP ESR1 CYP19A1
45 skeletal muscle neoplasm 12.3
46 dartoic leiomyoma 11.4
47 carney complex variant 11.3
48 skeletal muscle cancer 11.2
49 muscle cancer 11.2
50 mixed endometrial stromal and smooth muscle tumor 11.2

Graphical network of the top 20 diseases related to Myoma:



Diseases related to Myoma

Symptoms & Phenotypes for Myoma

UMLS symptoms related to Myoma:


muscle weakness, myoclonus, myalgia, torticollis, muscle cramp, muscle rigidity, muscle spasticity

MGI Mouse Phenotypes related to Myoma:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 CYP19A1 EGFR EPO ESR1 FH GNRH1
2 cellular MP:0005384 10.4 CYP19A1 EGFR EPO ESR1 FH KITLG
3 cardiovascular system MP:0005385 10.38 CYP19A1 EGFR EPO ESR1 KITLG KRAS
4 growth/size/body region MP:0005378 10.37 CYP19A1 EGFR ESR1 GNRH1 HPSE2 KITLG
5 endocrine/exocrine gland MP:0005379 10.31 CYP19A1 EGFR ESR1 GNRH1 KITLG KRAS
6 mortality/aging MP:0010768 10.3 EGFR EPO ESR1 FH HPSE2 KITLG
7 hematopoietic system MP:0005397 10.29 CYP19A1 EGFR EPO ESR1 GNRH1 KITLG
8 integument MP:0010771 10.29 CYP19A1 EGFR EPO ESR1 GNRH1 KITLG
9 digestive/alimentary MP:0005381 10.28 CYP19A1 EGFR ESR1 GNRH1 HPSE2 KITLG
10 embryo MP:0005380 10.27 EGFR EPO ESR1 KITLG KRAS LEP
11 immune system MP:0005387 10.26 CYP19A1 EGFR EPO ESR1 GNRH1 KITLG
12 limbs/digits/tail MP:0005371 10.15 EGFR EPO ESR1 KITLG KRAS LEP
13 nervous system MP:0003631 10.15 CYP19A1 EGFR ESR1 GNRH1 KITLG KRAS
14 liver/biliary system MP:0005370 10.13 CYP19A1 EGFR EPO ESR1 GNRH1 KITLG
15 muscle MP:0005369 10.09 CYP19A1 EGFR EPO ESR1 KRAS LEP
16 neoplasm MP:0002006 10.06 EGFR ESR1 GNRH1 KITLG KRAS LEP
17 normal MP:0002873 10.02 CYP19A1 EGFR EPO ESR1 GNRH1 KRAS
18 renal/urinary system MP:0005367 9.85 CYP19A1 EGFR ESR1 FH GNRH1 HPSE2
19 pigmentation MP:0001186 9.8 CYP19A1 EGFR KITLG KRAS LEP MFN2
20 reproductive system MP:0005389 9.7 CYP19A1 EGFR ESR1 GNRH1 KITLG KRAS
21 skeleton MP:0005390 9.44 CYP19A1 EGFR EPO ESR1 GNRH1 KITLG

Drugs & Therapeutics for Myoma

Drugs for Myoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
2
Dimenhydrinate Approved Phase 4 523-87-5 441281
3
Dienogest Approved Phase 4 65928-58-7
4
Desogestrel Approved Phase 4 54024-22-5 40973
5
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
6
Misoprostol Approved Phase 4 59122-46-2 5282381
7
Dinoprostone Approved Phase 4 363-24-6 5280360
8
Morphine Approved, Investigational Phase 4 57-27-2 5288826
9
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
10
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
11 Ulipristal acetate Phase 4 126784-99-4
12 Carboxymethylcellulose Sodium Phase 4
13 Progestins Phase 4
14 Contraceptive Agents, Male Phase 4
15 Hemostatics Phase 4
16 Coagulants Phase 4
17 Vasoconstrictor Agents Phase 4
18 Vasopressins Phase 4
19 Arginine Vasopressin Phase 4
20 Gastrointestinal Agents Phase 4
21 Anti-Arrhythmia Agents Phase 4
22 Antacids Phase 4
23 Anti-Ulcer Agents Phase 4
24 Anesthetics, Local Phase 4
25 Sodium Channel Blockers Phase 4
26 Diuretics, Potassium Sparing Phase 4
27 Estrogen Antagonists Phase 4
28 Estrogen Receptor Antagonists Phase 4
29 Estrogens Phase 4
30 Aromatase Inhibitors Phase 4
31 Contraceptive Agents Phase 4
32 Hormones Phase 4
33 Contraceptives, Oral Phase 4
34 Hormone Antagonists Phase 4
35 Contraceptives, Postcoital Phase 4
36
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
37
Tranexamic Acid Approved Phase 2, Phase 3 1197-18-8 5526
38
Simvastatin Approved Phase 3 79902-63-9 54454
39
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
40
Norethindrone Approved Phase 3 68-22-4 6230
41
Alprostadil Approved, Investigational Phase 2, Phase 3 745-65-3 149351 5280723
42
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
43
Lactitol Approved, Investigational Phase 2, Phase 3 585-88-6, 585-86-4 493591
44
Pembrolizumab Approved Phase 3 1374853-91-4
45
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
46
Gemcitabine Approved Phase 3 95058-81-4 60750
47
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
48
Ethanol Approved Phase 2, Phase 3 64-17-5 702
49
Fluoxymesterone Approved, Illicit Phase 3 76-43-7 6446
50
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067

Interventional clinical trials:

(show top 50) (show all 150)
# Name Status NCT ID Phase Drugs
1 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
2 Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2 Unknown status NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
3 Advantages of Ulipristal Acetate for the Preoperative Treatment of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
4 The Role of Seprafilm Bioresorbable Slurry in the Prevention of Intrauterine Synechiae in Patients Undergoing Hysteroscopic Myomectomy Unknown status NCT01632202 Phase 4
5 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
6 The Effect of UPA on Women Ovarian Reserve Unknown status NCT02361892 Phase 4 ulipristal acetate
7 Safety and Efficacy of Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy; A Randomized Controlled Trial Completed NCT03892668 Phase 4 Tranexamic Acid;oxytocin;placebo
8 GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study Completed NCT00743080 Phase 4
9 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
10 Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy: A Randomized Controlled Study Completed NCT02154932 Phase 4 2 doses 400 microgram misoprostol;single dose misoprostol
11 A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
12 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
13 SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle Completed NCT01242852 Phase 4
14 Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial Completed NCT01393704 Phase 4 Vasopressin
15 Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions Not yet recruiting NCT04364581 Phase 4 Letrozole;Placebo
16 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
17 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
18 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
19 the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation Unknown status NCT03483142 Phase 3 Misoprostol;Placebos
20 Efficacy and Safety of Pre-operative Vaginal Misoprostol in Reduction of Intraoperative Blood Loss During Myomectomy. Amulticentre Single Blind Randomized Trial. Unknown status NCT03509168 Phase 2, Phase 3 Misoprostol Pfizer Brand
21 Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients Unknown status NCT03134157 Phase 3 oral drug and vaginal placebo;oral drug and oral placebo;Vaginal placebo+ oral placebo
22 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
23 A Phase III, Randomised, Parallel Group, Double-blind, Double-dummy, Active Comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of PGL4001 vs GnRH-agonist for Pre-operative Ttt of Symptomatic Uterine Myomas Completed NCT00740831 Phase 3 PGL4001;leuprorelin
24 A Phase III, Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of PGL4001 (Ulipristal) Versus Placebo for Pre-Operative Treatment of Symptomatic Uterine Myomas Completed NCT00755755 Phase 3 PGL4001 (ulipristal) and iron;PGL4001 matching placebo and iron;PGL4001 (ulipristal) and iron
25 Mifepristone 5 mg Versus 10 mg During 6 Months for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial. Completed NCT00886873 Phase 2, Phase 3 Mifepristone
26 A Phase III, Multicentre, Randomized, Double-blind Clinical Study, Investigating the Efficacy and Safety of Repeated 12-week Courses of Daily 5mg or 10mg Doses of PGL4001 for the Long-term Management of Symptomatic Uterine Fibroids Completed NCT01629563 Phase 3 PGL4001 5 mg;PGL4001 10 mg
27 Use of Vasopressin Versus Epinephrine to Reduce Hemorrhage During Myomectomy: a Randomized Controlled Trial Completed NCT01861015 Phase 3 Epinephrine;Vasopressin
28 Placebo-controlled,Doubled,Randomized Trial Evaluating the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women Undergoing Laparoscopic Myomectomy Completed NCT01715597 Phase 3 ascorbic acid;Normal saline
29 Single-port Laparoscopic Myomectomy Using Barbed Suture Versus Multi-port One: a Multi-center Randomized Controlled Trial Completed NCT01984632 Phase 3
30 Randomized Controlled Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
31 A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of 3-months Open-label Treatment With PGL4001, Followed by a Randomised, Double-blind Placebo Controlled Period of 10 Days Treatment With Progestin, in Subjects With Myomas and Heavy Uterine Bleeding. Completed NCT01156857 Phase 3 PGL4001, placebo;PGL4001, progestin
32 A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of Three Successive Periods of 3-month Open-label PGL4001 Treatment, Each Followed by Ten Days of Double-blind Treatment With Progestin or Placebo and a Drug-free Period Until Return of Menses, in Subjects With Myomas and Heavy Uterine Bleeding Completed NCT01252069 Phase 3 PGL4001, placebo, drug free period;PGL4001, progestin, drug free period
33 A Phase III, Multicentre, Extension Study Investigating the Efficacy and Safety of Repeated Intermittent 3-month Courses of Open-label Administration of Ulipristal Acetate, in Subjects With Symptomatic Uterine Myomas and Heavy Uterine Bleeding Completed NCT01642472 Phase 3 Ulipristal Acetate - open label
34 Phase 1 Study of Misoprostol in Reducing Intraoperative Bleeding in Myomectomy Operations Completed NCT02061657 Phase 3 Misoprostol;Placebo( for misoprostol)
35 Mifepristone 5 mg Versus 10 mg for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial. Completed NCT00712595 Phase 2, Phase 3 Mifepristone;Mifepristone
36 Efficacy of Transcervical Vasopressin Injection VersusVaginal Misoprostol During Hysteroscopic Myomectomy in Reducing Operative Blood Loss and Operation Time: A Randomized Trial. Completed NCT03930069 Phase 2, Phase 3 Misoprostol;Vasopressin
37 Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner Completed NCT01064960 Phase 3
38 Aromatase Inhibitors or Gonadotropin-releasing Hormone Agonists for the Management of Uterine Adenomyosis: A Randomized Controlled Trial Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
39 Single Blinded Randomized Study of Volume Reduction of Uterine Fibroids After Uterine Artery Embolization Versus Computer Tomography or Ultrasound Guided Percutaneous Microwave Ablation Evaluated by Magnetic Resonance Imaging Recruiting NCT02942537 Phase 2, Phase 3
40 A Phase 3 Randomized Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-905) Recruiting NCT03924895 Phase 3 Pembrolizumab
41 A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866) Recruiting NCT03924856 Phase 3 Pembrolizumab;Gemcitabine;Cisplatin;Placebo
42 Uterus Transplantation From Live Donors and From Deceased Donors - Clinical Study Recruiting NCT03277430 Phase 3 Tacrolimus
43 Single Blinded Randomized Controlled Study of Symptom Improvement After Uterine Artery Embolization (UAE) Versus Ultrasound Guided Percutaneous/Transvaginal Microwave Ablation, Evaluated by Validated Questionnaires Not yet recruiting NCT04209127 Phase 2, Phase 3
44 A Randomized Controlled Trial of Hand-assisted Laparoscopic Myomectomy Versus Abdominal Myomectomy: Surgical Outcomes and Patient Satisfactions Terminated NCT01858454 Phase 3
45 Treatment of Uterine Myoma With 2.5 or 5 mg Mifepristone Daily During 3 Months With 9 Months Post-treatment Follow-up. Randomized Clinical Trial. Terminated NCT01786226 Phase 2, Phase 3 Oral administration of mifepristone 2.5 mg daily for three months;Oral administration of mifepristone 5 mg daily for three months
46 Open Label Phase II Clinical Trial of Myoma Immunotherapy Unknown status NCT03550703 Phase 2
47 A Controlled Randomized Multicenter Study to Assess the Safety and Performance of Adhibit™ Adhesion Prevention Gel in Myomectomy Surgery Completed NCT00562471 Phase 1, Phase 2
48 Laparoscopic Myomectomy Using Barbed or Conventional Sutures . A Randomized Controlled Trial Completed NCT02166411 Phase 2
49 The Efficacy and Safety of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Adhesions After Laparoscopic Gynecological Surgery: a Randomized Controlled Trial Completed NCT02166554 Phase 1, Phase 2
50 Fertility After Uterine Artery Embolisation for the Treatment of Leiomyomas Completed NCT00839722 Phase 2

Search NIH Clinical Center for Myoma

Cochrane evidence based reviews: myoma

Genetic Tests for Myoma

Anatomical Context for Myoma

MalaCards organs/tissues related to Myoma:

40
Uterus, Smooth Muscle, Cervix, Ovary, Testes, Breast, Bone

Publications for Myoma

Articles related to Myoma:

(show top 50) (show all 3719)
# Title Authors PMID Year
1
Minimally invasive approach for myomectomy. 61 54
20414845 2010
2
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. 54 61
19135657 2010
3
Interventions to reduce haemorrhage during myomectomy for fibroids. 54 61
19588371 2009
4
The aromatase expression in myomas and myometriums of women in reproduction and perimenopausal age. 54 61
20164038 2009
5
A systematic review of randomized controlled trials to reduce hemorrhage during myomectomy for uterine fibroids. 54 61
17894936 2008
6
Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use. 61 54
17616855 2007
7
Interventions to reduce haemorrhage during myomectomy for fibroids. 61 54
17253552 2007
8
Studies on leptin and leptin receptor gene expression in myometrium and uterine myomas of gnRH analogue-treated women. 54 61
17009630 2006
9
Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. 61 54
15377824 2005
10
Proliferative activity and level of steroid hormone receptors in the myometrium and myoma nodes in different phases of menstrual cycle. 61 54
14714093 2003
11
Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14). 54 61
11788889 2002
12
Levels of estrogen and progesterone receptors in the myometrium and leiomyoma tissue after suppression of estrogens with gonadotropin releasing hormone analogs. 54 61
12227888 2001
13
Tamoxifen treatment and gynecologic side effects: a review. 54 61
11336777 2001
14
Advances in uterine leiomyoma research: the progesterone hypothesis. 54 61
11035984 2000
15
Differential efficacy of gonadotropin-releasing hormone (GnRH) agonist treatment on pedunculated and degenerated myomas: a retrospective study of 630 women. 61 54
15512637 2000
16
Combining myoma coagulation with endometrial ablation/resection reduces subsequent surgery rates. 61 54
10694070 1999
17
Correlation between the growth of uterine leiomyomata and estrogen and progesterone receptor content in needle biopsy specimens. 61 54
9806586 1998
18
Cryomyolysis, a new procedure for the conservative treatment of uterine fibroids. 61 54
9454874 1998
19
[Value of premedication with gonadotropin releasing hormone agonists before transcervical resection of solitary submucous myoma]. 54 61
9206552 1996
20
[Research on the relationship between estrogen receptor, progesterone receptor, cell proliferation associated antigen in uterine leiomyoma and nuclear body density of myoma, serum reproductive hormone concentrations]. 54 61
8745507 1995
21
Progesterone: a critical role in the pathogenesis of uterine myomas. 61 54
7847524 1995
22
Production and characterization of monoclonal antibodies to shark cartilage proteoglycan. 54 61
7540474 1994
23
Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone. Analogue depot therapy. 54 61
8160541 1994
24
Pulmonary lymphangioleiomyomatosis. 54 61
8369788 1993
25
[Effect of decapeptyl (D-TrpG GnPh) on estrogen receptors, progesterone receptors and tissue levels of estrogens (non-conjugated and sulfate-conjugated) in patients with uterine myoma]. 54 61
2148976 1990
26
Progestin and antiprogestin interactions with progesterone receptors in human myomas. 61 54
1969820 1990
27
[The mechanism of the therapeutic effect of norethisterone in hyperplastic diseases of the endo- and myometrium in women of reproductive age]. 61 54
2198696 1990
28
Immunoreactive and estrogen-binding estrogen receptors, and progestin receptor levels in uterine leiomyomata and their parental myometrium. 54 61
2245811 1990
29
Cerebral infarction and iron deficiency anemia due to uterine myoma in two middle-aged women with histidine-rich glycoprotein deficiency. 61
32361514 2020
30
Comparison of Focused Ultrasound Surgery and Hysteroscopic Resection for Treatment of Submucosal Uterine Fibroids (FIGO Type 2). 61
32359807 2020
31
Transvaginal Ultrasound and Doppler Features of Intraligamental Myomas. 61
31944342 2020
32
Comparison of aspirating pipettes and hysteroscopy with curettage. 61
32350598 2020
33
Anxiety of myoma patients: results of standardized interviews with the State Trait Anxiety Inventory and the Kessler 10 questionnaire. 61
31179813 2020
34
Feasibility of Point Shear Wave Elastography for Evaluating Diabetic Peripheral Neuropathy. 61
31872909 2020
35
Giant subserosal myoma causing deep venous thrombosis in a patient with pre-existing May-Thurner syndrome. 61
32280393 2020
36
Use of GnRH Analogues in the Reduction of Submucous Fibroid for Surgical Hysteroscopy: A Systematic Review and Meta-Analysis. 61
32559802 2020
37
Administration of rectal cytotec versus rectal buscopan before hysteroscopy. 61
32491923 2020
38
Characterization and anti-uterine tumor effect of extract from Prunella vulgaris L. 61
32552673 2020
39
Hysterectomy Provides Benefit in Health-Related Quality of Life: A 10-Year Follow-up Study. 61
31404711 2020
40
Hemoperitoneum due to bleeding from a vein overlying a subserous uterine myoma: a case report. 61
32384913 2020
41
Abdominal Myomectomy for Huge Uterine Myomas with Intra-arterial Balloon Occlusion: Approach to Reduce Blood Loss. 61
32399486 2020
42
Comparison between transumbilical and transvaginal morcellation of a large uterus during single-port-access total laparoscopic hysterectomy. 61
32489984 2020
43
Single-Port/Pneumovagina Technique for Two Further Applications. 61
31265908 2020
44
In-bag manual versus uncontained power morcellation for laparoscopic myomectomy. 61
32374421 2020
45
The Focused Ultrasound Myoma Outcome Study (FUMOS); a retrospective cohort study on long-term outcomes of MR-HIFU therapy. 61
32040725 2020
46
One-Step Resection via Hysteroscopic Myomectomy and Prostaglandin F2α for Large Submucosal Myoma. 61
32105820 2020
47
Augmented Reality with Diffusion Tensor Imaging and Tractography during Laparoscopic Myomectomies. 61
31765829 2020
48
Laparoscopic Myomectomy. 61
32399488 2020
49
Submucosal Myoma Treatment for Women Who Wish to have Children in the Future Nodule Dissection Centripetal Cutting Method of TCR (Transcervical Resection). 61
32399491 2020
50
Crosslinked Hyaluronic Acid Gels for the Prevention of Intrauterine Adhesions after a Hysteroscopic Myomectomy in Women with Submucosal Myomas: A Prospective, Randomized, Controlled Trial. 61
32429137 2020

Variations for Myoma

Expression for Myoma

Search GEO for disease gene expression data for Myoma.

Pathways for Myoma

Pathways related to Myoma according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 KRAS KITLG EPO EGFR CALD1
2
Show member pathways
12.6 TP53 PGR KRAS ESR1 EGFR
3
Show member pathways
12.26 OXT KRAS EGFR CALD1 CALCA
4
Show member pathways
12.06 TP53 KRAS KITLG GNRH1 EGFR
5 11.89 TP53 KRAS KITLG FH ESR1 EPO
6 11.87 TP53 KRAS HPSE2 ESR1 EGFR
7 11.75 TP53 MED12 KRAS ESR1
8
Show member pathways
11.66 PGR KRAS ESR1 EGFR
9 11.59 TP53 KRAS EGFR
10 11.55 TP53 KRAS EGFR
11 11.54 TP53 KRAS ESR1 EGFR CYP19A1
12 11.52 TP53 MFN2 KRAS
13 11.33 KRAS ESR1 EGFR
14 10.86 KRAS EPO EGFR
15 10.03 ESR1 CYP19A1

GO Terms for Myoma

Cellular components related to Myoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 OXT MUC16 LEP KITLG GNRH1 EPO
2 extracellular region GO:0005576 9.28 OXT MUC16 LEP KITLG HPSE2 GNRH1

Biological processes related to Myoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.09 PGR OXT LEP KRAS KITLG GNRH1
2 positive regulation of transcription, DNA-templated GO:0045893 9.85 TP53 MED12 HMGA2 ESR1 EPO EGFR
3 positive regulation of cell proliferation GO:0008284 9.8 LEP KRAS KITLG HPSE2 EPO EGFR
4 positive regulation of protein kinase B signaling GO:0051897 9.76 LEP KITLG ESR1 EGFR
5 circadian rhythm GO:0007623 9.75 TP53 LEP EGFR
6 positive regulation of MAP kinase activity GO:0043406 9.65 KRAS KITLG EGFR
7 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.57 TP53 EGFR
8 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.56 TP53 ESR1
9 positive regulation of cold-induced thermogenesis GO:0120162 9.56 OXT MFN2 LEP FH
10 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.55 TP53 ESR1
11 response to salt stress GO:0009651 9.54 TP53 EPO
12 ovulation cycle GO:0042698 9.52 GNRH1 EGFR
13 response to prostaglandin E GO:0034695 9.51 OXT GNRH1
14 negative regulation of apoptotic process GO:0043066 9.5 TP53 LEP KITLG HMGA2 GNRH1 EPO
15 ovulation from ovarian follicle GO:0001542 9.49 PGR LEP
16 female pregnancy GO:0007565 9.46 OXT LEP KRAS GNRH1
17 negative regulation of calcium ion transport into cytosol GO:0010523 9.4 EPO CALCA
18 response to estradiol GO:0032355 9.02 OXT LEP ESR1 EGFR CYP19A1

Molecular functions related to Myoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase binding GO:0051117 9.33 PGR ESR1 EGFR
2 hormone activity GO:0005179 9.02 OXT LEP GNRH1 EPO CALCA
3 nitric-oxide synthase regulator activity GO:0030235 8.96 ESR1 EGFR

Sources for Myoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....